Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ABIPOL 5 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ABIPOL 5 MG CAPSULAS DURAS EFG

Approved

STANDARD

ABIPOL 5 MG CAPSULAS DURAS EFG

Abartis Pharma S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 1, 2023
Approval ID: caf361eefd3adada
Company: Abartis Pharma S.L.
Type: Standard

Approval Details

Approval Id: caf361eefd3adada
Drug Cima Aemps Name: ABIPOL 5 MG CAPSULAS DURAS EFG
Register Number: 88579
Holder Company Name: Abartis Pharma S.L.
Marketing Company Name: Abartis Pharma S.L.
Authorization Date: 2023-02-01
Dosage Form: CÁPSULA DURA
Dose: 5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Abartis Pharma S.L.

Active Ingredients

ARIPIPRAZOL

5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 1, 2023

Approval ID

caf361eefd3adada

Type

Standard

Back to CIMA-AEMPS Approvals